Acquisitions – We expect to meet our aggressive growth goals through internal growth matched with complementary acquisitions. There are many clinical-diagnostic companies that possess unique product offerings, but lack infrastructure or market reach. Magellan is one of the few mid-size bioscience companies with the scale and experience required to integrate these complementary companies while preserving their market strengths. Our acquisition strategy focuses on companies, technologies, and product lines where we can add value from our existing technology, know-how, infrastructure, and market or applications expertise. While past practice isn't necessarily a predictor of future performance, it can be illustrative. Magellan was created by the combination of two great companies – ESA and Dynex – and has grown through acquisition of a third – TREK. Each company has a strong brand that continues to be well-regarded in the marketplace, and proprietary technologies that enable us to serve the emerging growth areas of our core markets.